Trial Profile
Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROFILE
- Sponsors Novartis
- 14 Nov 2018 A 3 month interim results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 12 Oct 2017 Interim results of 3 month comparing satisfaction with previous treatment and fingolimod at three months, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 24 May 2017 Status changed from recruiting to completed.